Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Other financing activities (2023)

Ptc Therapeutics (PTCT) has 1 years of Other financing activities data on record, last reported at $85000.0 in Q3 2023.

  • For Q3 2023, Other financing activities changed N/A year-over-year to $85000.0; the TTM value through Dec 2023 reached $282000.0, changed N/A, while the annual FY2023 figure was $282000.0, 97.54% down from the prior year.
  • Other financing activities reached $85000.0 in Q3 2023 per PTCT's latest filing, up from $15000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $182000.0 in Q1 2023 and bottomed at $15000.0 in Q2 2023.